Dr. Yefu Liu 刘也夫
Chief Physician
Hepatobiliary and Pancreatic Surgery, Liaoning Cancer Hospital & Institute, Shenyang
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical and comprehensive treatment of hepatobiliary and pancreatic tumors, including minimally invasive procedures such as robotic-assisted pancreatoduodenectomy, modular pancreatectomy, spleen-preserving distal pancreatectomy, and anatomical liver resection.
Dr. Liu holds a medical doctorate and serves as Deputy Party Secretary, President of Liaoning Cancer Hospital & Institute, and Director of Liaoning Institute of Oncology. An academic leader in hepatobiliary and pancreatic surgery, Dr. Liu also directs the surgical teaching department and supervises doctoral candidates.
Professional roles
- Chair, Hepatobiliary Surgery Group, 9th Committee of Surgical Branch, Liaoning Medical Association
- Chair, 2nd Tumor Minimally Invasive Therapy Professional Committee, Liaoning Anti-Cancer Association
- Chair, Clinical Application and Ethics Committee for Human Organ Transplantation Technology, Liaoning Province
- Vice Chair, 2nd General Surgery Immunology Professional Committee, Liaoning Immunology Society
Name order: in Chinese the family name comes first (Liu Yefu). Papers usually list the name as Yefu Liu or Liu Y.
Selected publications
36 papers on PubMed matched by name and affiliation; 26 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Oncol, 2026 (senior author): Editorial: Novel anti-cancer agents targeting triple-negative breast cancer. PubMed 42751378
- J Nanobiotechnology, 2026 (senior author): Decoding triple negative breast cancer bone metastasis: from 3D bioprinted models to clinical translation. PubMed 42332744
- Hepatol Int, 2026 (senior author): Refining meta-analyses in advanced biliary tract cancer. PubMed 41109922
- Hepatol Int, 2026 (senior author): Recombinant human serum albumin: a true therapeutic substitute or merely a serum level elevator?. PubMed 40968193
- Int J Immunopathol Pharmacol, 2026 (senior author): Silencing RPL9 promotes malignant proliferation in breast cancer cells. PubMed 41877589
- Int J Surg, 2026 (senior author): Letter to the editor regarding "L-shaped association of selenium in blood metals mixtures with the incidence of liver fibrosis/cirrhosis: NHANES 2017-2020". PubMed 40932336
- Hum Mutat, 2025 (senior author): Consensus Integration of Multiomics Data With Machine Learning Algorithms Reveals Heterogeneous Molecular Subtypes and Enables Personalized Treatment Strategies for Hepatocellular Carcinoma. PubMed 41333555
- Eur J Cancer, 2025 (senior author): Letter Re: Association of comorbid schizophrenia with cancer stage at admission, treatments, length of stay, and 30-day in-hospital mortality in patients with pancreatic cancer: A retrospective matched-pair cohort study in Japan. PubMed 40886566
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion